[
  {
    "pmid": "29151359",
    "title": "Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer",
    "authors": "Soria JC, Ohe Y, Vansteenkiste J, et al.",
    "journal": "New England Journal of Medicine",
    "year": 2018,
    "abstract": "FLAURA trial: Osimertinib showed superior efficacy compared with standard EGFR-TKIs (erlotinib or gefitinib) in the first-line treatment of EGFR mutation-positive advanced NSCLC. The median progression-free survival was 18.9 months in the osimertinib group versus 10.2 months in the standard EGFR-TKI group. The overall survival was also significantly improved with osimertinib.",
    "key_finding": "Osimertinib demonstrated median PFS of 18.9 months vs 10.2 months for first-generation EGFR TKIs in first-line EGFR-mutant NSCLC",
    "biomarker": "EGFR",
    "cancer_type": "NSCLC"
  },
  {
    "pmid": "27959700",
    "title": "Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer",
    "authors": "Mok TS, Wu YL, Ahn MJ, et al.",
    "journal": "New England Journal of Medicine",
    "year": 2017,
    "abstract": "AURA3 trial: In patients with T790M-positive advanced NSCLC who had disease progression after first-line EGFR-TKI therapy, osimertinib resulted in significantly longer progression-free survival than platinum-pemetrexed chemotherapy. Median PFS was 10.1 months vs 4.4 months.",
    "key_finding": "Osimertinib showed median PFS of 10.1 months vs 4.4 months for chemotherapy in T790M-positive NSCLC after first-line EGFR-TKI progression",
    "biomarker": "EGFR_T790M",
    "cancer_type": "NSCLC"
  },
  {
    "pmid": "28586279",
    "title": "Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer",
    "authors": "Peters S, Camidge DR, Shaw AT, et al.",
    "journal": "New England Journal of Medicine",
    "year": 2017,
    "abstract": "ALEX trial: Alectinib showed superior efficacy and lower toxicity compared with crizotinib in patients with previously untreated, ALK-positive NSCLC. Median PFS was 34.8 months with alectinib compared to 10.9 months with crizotinib. CNS progression was significantly lower with alectinib.",
    "key_finding": "Alectinib demonstrated median PFS of 34.8 months vs 10.9 months for crizotinib with superior CNS activity in first-line ALK+ NSCLC",
    "biomarker": "ALK",
    "cancer_type": "NSCLC"
  },
  {
    "pmid": "34096690",
    "title": "Sotorasib for KRAS p.G12C-Mutated Non-Small-Cell Lung Cancer",
    "authors": "Skoulidis F, Li BT, Dy GK, et al.",
    "journal": "New England Journal of Medicine",
    "year": 2021,
    "abstract": "CodeBreaK 100 trial: Sotorasib, a KRAS G12C inhibitor, showed durable clinical benefit in patients with KRAS p.G12C-mutated advanced NSCLC who had received prior therapy. Objective response rate was 37.1%, and median PFS was 6.8 months.",
    "key_finding": "Sotorasib achieved ORR of 37.1% and median PFS of 6.8 months in previously treated KRAS G12C mutant NSCLC",
    "biomarker": "KRAS_G12C",
    "cancer_type": "NSCLC"
  },
  {
    "pmid": "29658856",
    "title": "Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer",
    "authors": "Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al.",
    "journal": "New England Journal of Medicine",
    "year": 2018,
    "abstract": "KEYNOTE-189 trial: The addition of pembrolizumab to standard chemotherapy resulted in significantly longer overall survival and progression-free survival than chemotherapy alone in metastatic nonsquamous NSCLC. Benefit was observed regardless of PD-L1 expression level.",
    "key_finding": "Pembrolizumab plus chemotherapy showed median OS of 22.0 months vs 10.7 months for chemotherapy alone regardless of PD-L1 status",
    "biomarker": "PD-L1",
    "cancer_type": "NSCLC"
  },
  {
    "pmid": "30280635",
    "title": "Lorlatinib in ALK-Positive Non-Small-Cell Lung Cancer",
    "authors": "Solomon BJ, Besse B, Bauer TM, et al.",
    "journal": "New England Journal of Medicine",
    "year": 2020,
    "abstract": "CROWN trial: First-line lorlatinib significantly improved progression-free survival compared with crizotinib in patients with advanced ALK-positive NSCLC. At 12 months, 78% of patients in the lorlatinib group were alive without disease progression. Superior intracranial activity was observed.",
    "key_finding": "Lorlatinib showed 12-month PFS rate of 78% with superior intracranial response rates compared to crizotinib in first-line ALK+ NSCLC",
    "biomarker": "ALK",
    "cancer_type": "NSCLC"
  },
  {
    "pmid": "31150573",
    "title": "Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer",
    "authors": "Camidge DR, Kim HR, Ahn MJ, et al.",
    "journal": "New England Journal of Medicine",
    "year": 2018,
    "abstract": "ALTA-1L trial: Brigatinib showed superior efficacy compared with crizotinib in patients with ALK-positive NSCLC who had not previously received an ALK inhibitor. Median PFS was 24 months vs 11 months. Intracranial response rate was 78% vs 29%.",
    "key_finding": "Brigatinib demonstrated median PFS of 24 months vs 11 months for crizotinib with intracranial response rate of 78% in first-line ALK+ NSCLC",
    "biomarker": "ALK",
    "cancer_type": "NSCLC"
  },
  {
    "pmid": "33096232",
    "title": "Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer",
    "authors": "Wolf J, Seto T, Han JY, et al.",
    "journal": "New England Journal of Medicine",
    "year": 2020,
    "abstract": "GEOMETRY mono-1 trial: Capmatinib showed substantial activity in patients with NSCLC harboring MET exon 14 skipping mutation. ORR was 68% in treatment-naive patients and 41% in previously treated patients. Responses were durable.",
    "key_finding": "Capmatinib achieved ORR of 68% in treatment-naive and 41% in previously treated MET exon 14 skipping NSCLC patients",
    "biomarker": "MET",
    "cancer_type": "NSCLC"
  },
  {
    "pmid": "32846060",
    "title": "Entrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer",
    "authors": "Drilon A, Siena S, Dziadziuszko R, et al.",
    "journal": "Journal of Clinical Oncology",
    "year": 2020,
    "abstract": "Integrated analysis of ALKA, STARTRK-1, and STARTRK-2: Entrectinib demonstrated durable clinical benefit in ROS1 fusion-positive NSCLC. ORR was 67%, and intracranial ORR in patients with CNS disease was 55%.",
    "key_finding": "Entrectinib showed ORR of 67% with intracranial ORR of 55% in ROS1 fusion-positive NSCLC",
    "biomarker": "ROS1",
    "cancer_type": "NSCLC"
  },
  {
    "pmid": "32668111",
    "title": "Trastuzumab Deruxtecan in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer",
    "authors": "Li BT, Smit EF, Goto Y, et al.",
    "journal": "New England Journal of Medicine",
    "year": 2022,
    "abstract": "DESTINY-Lung01 trial: Trastuzumab deruxtecan showed significant antitumor activity in patients with previously treated HER2-mutant NSCLC. ORR was 55%, and median PFS was 8.2 months.",
    "key_finding": "Trastuzumab deruxtecan achieved ORR of 55% and median PFS of 8.2 months in previously treated HER2-mutant NSCLC",
    "biomarker": "HER2",
    "cancer_type": "NSCLC"
  },
  {
    "pmid": "33513356",
    "title": "Dabrafenib plus Trametinib in BRAF V600E-Mutated Non-Small-Cell Lung Cancer",
    "authors": "Planchard D, Smit EF, Groen HJM, et al.",
    "journal": "Journal of Clinical Oncology",
    "year": 2017,
    "abstract": "Combined BRAF and MEK inhibition with dabrafenib and trametinib showed substantial antitumor activity in BRAF V600E-mutated NSCLC. ORR was 64% in previously treated patients with median PFS of 10.9 months.",
    "key_finding": "Dabrafenib plus trametinib achieved ORR of 64% and median PFS of 10.9 months in BRAF V600E-mutated NSCLC",
    "biomarker": "BRAF_V600E",
    "cancer_type": "NSCLC"
  },
  {
    "pmid": "29431713",
    "title": "Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer",
    "authors": "Reck M, Rodriguez-Abreu D, Robinson AG, et al.",
    "journal": "New England Journal of Medicine",
    "year": 2016,
    "abstract": "KEYNOTE-024 trial: First-line pembrolizumab monotherapy prolonged progression-free and overall survival compared with chemotherapy in patients with PD-L1 TPS \u226550% advanced NSCLC. Median PFS was 10.3 months vs 6.0 months.",
    "key_finding": "Pembrolizumab monotherapy showed median PFS of 10.3 months vs 6.0 months for chemotherapy in PD-L1 \u226550% NSCLC",
    "biomarker": "PD-L1_high",
    "cancer_type": "NSCLC"
  },
  {
    "pmid": "30932520",
    "title": "Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer",
    "authors": "Antonia SJ, Villegas A, Daniel D, et al.",
    "journal": "New England Journal of Medicine",
    "year": 2018,
    "abstract": "PACIFIC trial: Consolidation durvalumab after concurrent chemoradiotherapy significantly improved progression-free and overall survival in stage III, unresectable NSCLC. Median PFS was 16.8 months vs 5.6 months with placebo.",
    "key_finding": "Durvalumab consolidation showed median PFS of 16.8 months vs 5.6 months for placebo after chemoradiation in stage III NSCLC",
    "biomarker": "stage_III",
    "cancer_type": "NSCLC"
  },
  {
    "pmid": "33767520",
    "title": "Adagrasib in KRAS G12C-Mutated Non-Small-Cell Lung Cancer",
    "authors": "Janne PA, Riely GJ, Gadgeel SM, et al.",
    "journal": "New England Journal of Medicine",
    "year": 2022,
    "abstract": "KRYSTAL-1 trial: Adagrasib, a KRAS G12C inhibitor, demonstrated clinical activity in previously treated KRAS G12C-mutated NSCLC. ORR was 43% with median PFS of 6.5 months. Activity observed in patients with CNS metastases.",
    "key_finding": "Adagrasib achieved ORR of 43% and median PFS of 6.5 months with intracranial activity in KRAS G12C NSCLC",
    "biomarker": "KRAS_G12C",
    "cancer_type": "NSCLC"
  },
  {
    "pmid": "32668118",
    "title": "Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer",
    "authors": "Park K, Haura EB, Leighl NB, et al.",
    "journal": "Journal of Clinical Oncology",
    "year": 2021,
    "abstract": "CHRYSALIS trial: Amivantamab, an EGFR-MET bispecific antibody, showed clinical activity in EGFR exon 20 insertion-mutated NSCLC progressing after platinum-based chemotherapy. ORR was 40% with median DOR of 11.1 months.",
    "key_finding": "Amivantamab achieved ORR of 40% in EGFR exon 20 insertion NSCLC after chemotherapy progression",
    "biomarker": "EGFR_exon20ins",
    "cancer_type": "NSCLC"
  },
  {
    "pmid": "35108058",
    "title": "Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer",
    "authors": "Drilon A, Oxnard GR, Tan DSW, et al.",
    "journal": "New England Journal of Medicine",
    "year": 2020,
    "abstract": "LIBRETTO-001 trial: Selpercatinib showed efficacy in RET fusion-positive NSCLC. In previously treated patients, ORR was 64%. In treatment-naive patients, ORR was 85%. Responses were durable with manageable toxicity.",
    "key_finding": "Selpercatinib achieved ORR of 64% in previously treated and 85% in treatment-naive RET fusion-positive NSCLC",
    "biomarker": "RET",
    "cancer_type": "NSCLC"
  },
  {
    "pmid": "34767761",
    "title": "Osimertinib Plus Chemotherapy in EGFR-Mutated Non-Small-Cell Lung Cancer",
    "authors": "Planchard D, Janne PA, Cheng Y, et al.",
    "journal": "New England Journal of Medicine",
    "year": 2023,
    "abstract": "FLAURA2 trial: First-line osimertinib plus chemotherapy significantly improved PFS compared with osimertinib alone in EGFR-mutated advanced NSCLC. Median PFS was 25.5 months vs 16.7 months.",
    "key_finding": "Osimertinib plus chemotherapy showed median PFS of 25.5 months vs 16.7 months for osimertinib alone in first-line EGFR-mutant NSCLC",
    "biomarker": "EGFR",
    "cancer_type": "NSCLC"
  },
  {
    "pmid": "35020613",
    "title": "Tepotinib in MET Exon 14 Skipping Non-Small-Cell Lung Cancer",
    "authors": "Le X, Sakai H, Felip E, et al.",
    "journal": "Journal of Clinical Oncology",
    "year": 2022,
    "abstract": "VISION trial: Tepotinib demonstrated substantial and durable efficacy in MET exon 14 skipping NSCLC. ORR was 46% in combined analysis with median DOR of 11.1 months.",
    "key_finding": "Tepotinib achieved ORR of 46% with durable responses in MET exon 14 skipping NSCLC",
    "biomarker": "MET",
    "cancer_type": "NSCLC"
  },
  {
    "pmid": "33798506",
    "title": "Larotrectinib in TRK Fusion-Positive Cancers",
    "authors": "Hong DS, DuBois SG, Kummar S, et al.",
    "journal": "Lancet Oncology",
    "year": 2020,
    "abstract": "Pooled analysis: Larotrectinib demonstrated rapid and durable responses in TRK fusion-positive cancers across tumor types. ORR was 79% with median DOR of 35.2 months.",
    "key_finding": "Larotrectinib achieved ORR of 79% with median DOR of 35.2 months across TRK fusion-positive tumor types",
    "biomarker": "NTRK",
    "cancer_type": "Various"
  },
  {
    "pmid": "32894689",
    "title": "Pralsetinib in RET-Altered Non-Small-Cell Lung Cancer",
    "authors": "Gainor JF, Curigliano G, Kim DW, et al.",
    "journal": "Lancet Oncology",
    "year": 2021,
    "abstract": "ARROW trial: Pralsetinib showed robust efficacy in RET fusion-positive NSCLC. ORR was 61% in previously treated patients and 70% in treatment-naive patients.",
    "key_finding": "Pralsetinib achieved ORR of 61% in previously treated and 70% in treatment-naive RET fusion-positive NSCLC",
    "biomarker": "RET",
    "cancer_type": "NSCLC"
  },
  {
    "pmid": "35320641",
    "title": "Trastuzumab Deruxtecan in HER2-Low Breast Cancer",
    "authors": "Modi S, Jacot W, Yamashita T, et al.",
    "journal": "New England Journal of Medicine",
    "year": 2022,
    "abstract": "DESTINY-Breast04 trial: Trastuzumab deruxtecan significantly improved PFS and OS compared with chemotherapy in HER2-low metastatic breast cancer. Median PFS 10.1 vs 5.4 months, median OS 23.9 vs 17.5 months. Established new treatment paradigm for HER2-low disease.",
    "key_finding": "T-DXd showed median PFS of 10.1 months vs 5.4 months in HER2-low metastatic breast cancer, defining a new targetable population",
    "biomarker": "HER2-low",
    "cancer_type": "Breast"
  },
  {
    "pmid": "34921995",
    "title": "Pembrolizumab in Early Triple-Negative Breast Cancer",
    "authors": "Schmid P, Cortes J, Dent R, et al.",
    "journal": "New England Journal of Medicine",
    "year": 2022,
    "abstract": "KEYNOTE-522 event-free survival analysis: Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab significantly improved EFS compared with neoadjuvant chemotherapy alone. EFS HR 0.63, 3-year EFS 84.5% vs 76.8%.",
    "key_finding": "Neoadjuvant/adjuvant pembrolizumab improved 3-year EFS to 84.5% vs 76.8% in early TNBC",
    "biomarker": "TNBC",
    "cancer_type": "Breast"
  },
  {
    "pmid": "34619777",
    "title": "Olaparib in Early Breast Cancer with BRCA Mutation",
    "authors": "Tutt ANJ, Garber JE, Kaufman B, et al.",
    "journal": "New England Journal of Medicine",
    "year": 2021,
    "abstract": "OlympiA trial: Adjuvant olaparib significantly improved invasive disease-free survival in patients with germline BRCA1/2 mutations and HER2-negative high-risk early breast cancer. 3-year iDFS 85.9% vs 77.1%, HR 0.58.",
    "key_finding": "Adjuvant olaparib improved 3-year iDFS to 85.9% vs 77.1% in gBRCA1/2-mutated HER2-negative early breast cancer",
    "biomarker": "BRCA",
    "cancer_type": "Breast"
  },
  {
    "pmid": "33539533",
    "title": "Abemaciclib in High-Risk HR+ Early Breast Cancer",
    "authors": "Johnston SRD, Harbeck N, Hegg R, et al.",
    "journal": "Journal of Clinical Oncology",
    "year": 2020,
    "abstract": "monarchE trial: Adjuvant abemaciclib plus endocrine therapy improved iDFS in high-risk HR+/HER2- early breast cancer. 2-year iDFS 92.2% vs 88.7%, HR 0.75. Benefit seen across subgroups.",
    "key_finding": "Adjuvant abemaciclib improved 2-year iDFS to 92.2% vs 88.7% in high-risk HR+/HER2- early breast cancer",
    "biomarker": "HR+",
    "cancer_type": "Breast"
  },
  {
    "pmid": "32955177",
    "title": "Pembrolizumab in MSI-H Metastatic Colorectal Cancer",
    "authors": "Andre T, Shiu KK, Kim TW, et al.",
    "journal": "New England Journal of Medicine",
    "year": 2020,
    "abstract": "KEYNOTE-177 trial: First-line pembrolizumab significantly improved PFS compared with chemotherapy in MSI-H/dMMR metastatic CRC. Median PFS 16.5 vs 8.2 months, HR 0.60. Established immunotherapy as standard first-line for MSI-H CRC.",
    "key_finding": "First-line pembrolizumab doubled PFS to 16.5 months vs 8.2 months in MSI-H metastatic CRC",
    "biomarker": "MSI-H",
    "cancer_type": "Colorectal"
  },
  {
    "pmid": "31566309",
    "title": "Encorafenib Plus Cetuximab in BRAF V600E CRC",
    "authors": "Kopetz S, Grothey A, Yaeger R, et al.",
    "journal": "New England Journal of Medicine",
    "year": 2019,
    "abstract": "BEACON trial: Encorafenib plus cetuximab (with or without binimetinib) significantly improved OS compared with standard therapy in BRAF V600E-mutated metastatic CRC. Median OS 9.0 vs 5.4 months.",
    "key_finding": "Encorafenib plus cetuximab improved median OS to 9.0 months vs 5.4 months in BRAF V600E mCRC",
    "biomarker": "BRAF_V600E",
    "cancer_type": "Colorectal"
  },
  {
    "pmid": "36264841",
    "title": "Sotorasib Plus Panitumumab in KRAS G12C CRC",
    "authors": "Fakih MG, Kopetz S, Kuboki Y, et al.",
    "journal": "New England Journal of Medicine",
    "year": 2023,
    "abstract": "CodeBreaK 300 trial: Sotorasib plus panitumumab significantly improved PFS compared with standard of care in previously treated KRAS G12C-mutated metastatic CRC. Median PFS 5.6 vs 2.2 months.",
    "key_finding": "Sotorasib plus panitumumab improved median PFS to 5.6 months in KRAS G12C mCRC - first targeted therapy for KRAS-mutated CRC",
    "biomarker": "KRAS_G12C",
    "cancer_type": "Colorectal"
  },
  {
    "pmid": "35139270",
    "title": "Relatlimab Plus Nivolumab in Untreated Advanced Melanoma",
    "authors": "Tawbi HA, Schadendorf D, Lipson EJ, et al.",
    "journal": "New England Journal of Medicine",
    "year": 2022,
    "abstract": "RELATIVITY-047 trial: Relatlimab plus nivolumab showed superior PFS compared with nivolumab alone in previously untreated advanced melanoma. Median PFS 10.1 vs 4.6 months, HR 0.75.",
    "key_finding": "Relatlimab + nivolumab (LAG-3 + PD-1) improved median PFS to 10.1 months vs 4.6 months in advanced melanoma",
    "biomarker": "LAG-3",
    "cancer_type": "Melanoma"
  },
  {
    "pmid": "34583430",
    "title": "Neoadjuvant Pembrolizumab in Resectable Stage III/IV Melanoma",
    "authors": "Patel SP, Othus M, Chen Y, et al.",
    "journal": "New England Journal of Medicine",
    "year": 2023,
    "abstract": "SWOG S1801 trial: Neoadjuvant plus adjuvant pembrolizumab significantly improved event-free survival compared with adjuvant pembrolizumab alone in resectable stage III/IV melanoma. 2-year EFS 72% vs 49%.",
    "key_finding": "Neoadjuvant pembrolizumab improved 2-year EFS to 72% vs 49% in resectable stage III/IV melanoma",
    "biomarker": "PD-1",
    "cancer_type": "Melanoma"
  },
  {
    "pmid": "28891408",
    "title": "Adjuvant Nivolumab vs Ipilimumab in Resected Stage III/IV Melanoma",
    "authors": "Weber J, Mandala M, Del Vecchio M, et al.",
    "journal": "New England Journal of Medicine",
    "year": 2017,
    "abstract": "CheckMate 238 trial: Adjuvant nivolumab significantly improved recurrence-free survival compared with ipilimumab in resected stage IIIB-IV melanoma. 12-month RFS 70.5% vs 60.8%.",
    "key_finding": "Adjuvant nivolumab improved 12-month RFS to 70.5% vs 60.8% compared with ipilimumab",
    "biomarker": "PD-1",
    "cancer_type": "Melanoma"
  }
]